Document:

EX-10.27

 Exhibit 10.27 

LOCK-UP AGREEMENT 

                     , 2014

 RBC Capital Markets, LLC 
 As Representative
of the Several Underwriters 
 3 World Financial Center 
 200
Vesey Street 
 New York, NY, 10281 
 Re: SCYNEXIS, Inc. (the
“Company”) 
 Ladies and Gentlemen: 

The undersigned is an owner of record or beneficially of certain shares of common stock of the Company (“Common Stock”) or
securities convertible into or exchangeable or exercisable for Common Stock. The Company proposes to carry out a public offering of Common Stock (the “Offering”) for which you will act as the representative (the
“Representative”) of the several underwriters named in Schedule I to the underwriting agreement (the “Underwriters”) to be entered into between the Underwriters and the Company with respect to the Offering (the “Underwriting
Agreement”). The undersigned recognizes that the Offering will be of benefit to the undersigned and will benefit the Company by, among other things, raising additional capital for its operations. The undersigned acknowledges that you and the
other Underwriters are relying on the representations and agreements of the undersigned contained in this letter in carrying out the Offering and in entering into the Underwriting Agreement. 

In consideration of the foregoing, the undersigned hereby agrees that the undersigned will not (and will use reasonable best efforts to cause
any spouse or immediate family member of the spouse or the undersigned living in the undersigned’s household not to), without the prior written consent of the Representative (which consent may be withheld in its sole discretion), directly or
indirectly, sell, offer, contract or grant any option to sell (including without limitation any short sale), grant any option, right or warrant to purchase, pledge, transfer, establish an open “put equivalent position” within the meaning
of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), lend or otherwise dispose of any shares of Common Stock, options, rights or warrants to acquire shares of Common Stock, or securities exchangeable
or exercisable for or convertible into shares of Common Stock currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned (or such spouse or family member), including, without
limitation, entering into any swap or other arrangement that transfers, in whole or in part, the economic consequences of the ownership of Common Stock or publicly announce an intention to do any of the foregoing, for a period commencing on the date
hereof and continuing through the close of trading on the date 180 days after the date of the final prospectus relating to the Offering (the “Restricted Period”). The foregoing sentence shall not apply to (a) transfers of shares of
Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as a bona fide gift, (b) distributions of shares of Common Stock or any security convertible into or exercisable or

 
exchangeable for Common Stock to partners, members or stockholders of the undersigned, (c) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable
for Common Stock by will or intestate succession or to any trust or partnership for the direct or indirect benefit of such person or any member of the immediate family of the undersigned, (d) transactions relating to shares of Common Stock or
other securities acquired in open market transactions after the completion of the Offering, or (e) the exercise of, and the surrender of shares of Common Stock directly to the Company pursuant to tax withholding or net exercise provisions of,
any equity awards issued pursuant to the Company’s equity incentive plans, which equity incentive plans exist at the time of the Offering; provided that (i) in the case of (a) – (c) above, each donee, distributee and
transferee, shall sign and deliver a lock-up letter substantially in the form of this letter, and (ii) in the case of (a),—(d) above, no filing under Section 16(a) of the Exchange Act shall
be required or shall be voluntarily made during the Restricted Period in connection with such event. In addition, the foregoing restrictions shall not apply to the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for
the transfer of shares of Common Stock; provided that (i) such plan does not provide for the transfer of Common Stock during the Restricted Period, and (ii) no public announcement or filing under the Exchange Act is required of or
voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan. For purposes of this letter agreement, “immediate family” shall mean any relationship by blood, marriage, domestic
partnership or adoption, not more remote than first cousin. 
 If the undersigned is an officer or director of the Company and if the
Representative determines in its sole discretion to consent to a requested release or waiver of the foregoing restrictions in connection with a transfer of Common Stock, (i) as required by FINRA, the Representative intends to notify the Company
of the impending release or waiver at least three business days before the effective date of such release or waiver, and (ii) the Company (in accordance with the provisions of the Underwriting Agreement) will announce the impending release or
waiver by press release through a major news service, or by any other means expressly permitted by FINRA, at least two business days before the effective date of the release or waiver. Any release or waiver granted by the Representative hereunder to
any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if both (a) the release or waiver is effected solely to permit a transfer
not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this letter agreement that are applicable to the transferor to the extent and for the duration that such terms remain in effect at the
time of the transfer. 
 The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s
transfer agent and registrar against the transfer of Common Stock or securities convertible into or exchangeable or exercisable for Common Stock held by the undersigned except in compliance with the foregoing restrictions, and any duly appointed
transfer agent and registrar for the registration or transfer of the Common Stock described herein are hereby authorized to decline to make any transfer of such Common Stock if such transfer would constitute a violation or breach of this agreement.

 With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of
any Common Stock owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. 

 This letter agreement shall automatically terminate upon the earlier to occur, if any, of
(a) the date on which the Company, or the Representatives, advises the other party in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, or (b) termination of the
Underwriting Agreement before the closing of the Public Offering. Notwithstanding the foregoing, in the event that the Public Offering is not consummated on or before September 30, 2014, this letter agreement shall terminate and its
provisions shall be of no further force and effect. 
 This agreement is irrevocable and will be binding on the undersigned and the
respective successors, heirs, personal representatives, and assigns of the undersigned. 
  

	
	
	
	By:
	Signature
	
	   

	 Printed Name of Person Signing
 (and indicate
capacity of person signing
 if signing as custodian, trustee, or on

behalf of an entity)EX-10.28

 Exhibit 10.28 

PATENT ASSIGNMENT 
 THIS
PATENT ASSIGNMENT is executed by Merck Sharp & Dohme Corp., a New Jersey corporation with a principal place of business at One Merck Drive, Whitehouse Station, New Jersey 08889 (“Assignor”) for the benefit of Scynexis, Inc., a
Delaware corporation with a principal place of business at 3501 C Tricenter Boulevard, Durham, NC 27713 (“Assignee”). 

RECITALS 
 Whereas, the
Assignor owns certain rights, title and interest in, to and under the patents set forth in the Patent Schedule attached hereto (“the Patents”), each of which is related to enfumafungin. 

Whereas, the Assignee is desirous of acquiring or confirming all of Assignor’s rights, title and interest in, to and under the Patents.

 To effect such transactions and in consideration of the foregoing and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, and intending to be legal bound hereby, the parties agree as follows: 
 TERMS 

Section 1 Assignment. The Assignor hereby conveys, transfers, assigns to, and confirms in the Assignee its entire right,
title and interest in, to and under the Patents, any continuation, divisional and continuation-in-part patent applications directed to the same invention as, and claiming priority to, the Patents, as well as any patents that issue therefrom
including all extensions, renewals, reissues, reexaminations and foreign counterparts thereof. 
 Section 2 Prosecution,
Maintenance, and Enforcement Responsibilities. 
 Assignee shall assume and be responsible for prosecuting, maintaining and enforcing the Patents
assigned herein. 
 Section 3 Assignment Recordation. The responsibility and cost of recording the present instrument
assignment the Patents assigned herein or any assignment of any other patent applications arising from the Patents shall be borne solely by Assignee. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties have caused this Patent Assignment to be executed as of
the date written below. 
  

					
		 	(“ASSIGNOR”)
		
		 	Merck Sharp & Dohme Corp.
		
	By:	 	 /s/ Iain D. Dukes

		 	Signatory:	 	 Iain D. Dukes

		 	Title & Position:	 	Senior Vice President, Worldwide Licensing
		 		 	 And External Research

 Executed this 28th day of January, in the year 2014. 

At 
 State of
    Pennsylvania     
 County of     Montgomery     

Before me personally appeared Iain D. Dukes who acknowledged the foregoing instrument to be a free act and deed and also represented that he is
a Senior Vice President, Worldwide Licensing and External Research at Merck Sharp & Dohme Corp., and is authorized to execute [and seal] the same this 28 day of January, in the year 2014. 

 

	
	 /s/ Marietta V. Quigg

	
	(Notary Public)
	
	My Commission expires:

  
 

 

 PATENT SCHEDULE 

TITLE:        ANTIFUNGAL AGENT 
  

																			
	 Country
	 	 Application No.
	  	 	 	 Filing Date
	  	 	 	 Publication No.
	  	 	 	 Patent No.
	  	 	 	 Issue Date

	 Australia
	 	22529/97	  		 	01/27/1997	  		 		  		 	703925	  		 	07/15/1999
	 Canada
	 	2244142	  		 	01/27/1997	  		 		  		 	2244142	  		 	03/29/2005
	 France
	 	97906885.5	  		 	01/27/1997	  		 	0877618	  		 	0877618	  		 	01/02/2003
	 Germany
	 	97906885.5	  		 	01/27/1997	  		 	0877618	  		 	69718141.3-08	  		 	01/02/2003
	 Great Britain
	 	97906885.5	  		 	01/27/1997	  		 	0877618	  		 	0877618	  		 	01/02/2003
	 Italy
	 	97906885.5	  		 	01/27/1997	  		 	0877618	  		 	0877618	  		 	01/02/2003
	 Japan
	 	527855/97	  		 	01/27/1997	  		 		  		 	3834062	  		 	07/28/2006
	 Spain
	 	97906885.5	  		 	01/27/1997	  		 	0877618	  		 	2188899	  		 	01/02/2003
	  

TITLE:        PROCESSES FOR ISOLATION AND PURIFICATION OF ENFUMAFUNGIN

 

	 Country
	 	 Application No.
	  	 	 	 Filing Date
	  	 	 	 Publication No.
	  	 	 	 Patent No.
	  	 	 	 Issue Date

	 Argentina
	 	P100103198	  		 	09/01/2010	  		 	AR078248A1	  		 		  		 	
	 EPC
	 	10814329.8	  		 	08/30/2010	  		 	2473169	  		 		  		 	
	 Taiwan
	 	099129753	  		 	09/02/2010	  		 		  		 		  		 	
	 United States
	 	13/393638	  		 	08/30/2010	  		 	US2012-0165513	  		 		  		 	

  

  
 Page 1 of 4 

 PATENT SCHEDULE 

TITLE:        ANTIFUNGAL AGENTS 
  

															
	 Country
	 	 Application No.
	  	 	 	 Filing Date
	  	 	 	 Patent No.
	  	 	 	 Issue Date

	 Australia
	 	2009282476	  		 	8/10/2009	  		 		  		 	
	 Canada
	 	2,731,696	  		 	8/10/2009	  		 		  		 	
	 China
	 	200980140551.5	  		 	8/10/2009	  		 		  		 	
	 Europe
	 	9806946.1	  		 	8/10/2009	  		 		  		 	
	 India
	 	404/KOLNP/2011	  		 	8/10/2009	  		 		  		 	
	 Japan
	 	2011-522977	  		 	8/10/2009	  		 		  		 	
	 United States
	 	13/058,227	  		 	5/26/2011	  		 		  		 	
	 WIPO
	 	PCT/US09/004569	  		 	8/10/2009	  		 		  		 	
	  

TITLE:        ANTIFUNGAL AGENTS
  
	  		 	
	 Country
	 	 Application No.
	  	 	 	 Filing Date
	  	 	 	 Patent No.
	  	 	 	 Issue Date

	 Australia
	 	2008307664	  		 	9/25/2008	  		 	2008307664	  		 	5/16/2013
	 Canada
	 	2,700,530	  		 	9/25/2008	  		 		  		 	
	 China
	 	200880116560.6	  		 	9/25/2008	  		 		  		 	
	 Europe
	 	08836095.3	  		 	9/25/2008	  		 		  		 	
	 India
	 	1241/KOLNP/2010	  		 	9/25/2008	  		 		  		 	
	 Japan
	 	2010-526940	  		 	9/25/2008	  		 		  		 	
	 United States
	 	12/680,472	  		 	2/18/2011	  		 	8,222,255	  		 	7/17/2012
	 WO
	 	PCT/US2008/011100	  		 	9/25/2008	  		 		  		 	

  

  
 Page 2 of 4 

 PATENT SCHEDULE 

TITLE:        ANTIFUNGAL AGENTS 
  

															
	 Country
	 	 Application No.
	 	 	  	 Filing Date
	 	 	  	 Patent No.
	 	 	  	 Issue Date

	 Australia
	 	2007245024	 		  	3/29/2007	 		  	2007245024	 		  	12/20/2012
	 Belgium
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 Canada
	 	2,649,432	 		  	3/29/2007	 		  		 		  	
	 Switzerland
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 China
	 	200780019497.X	 		  	3/29/2007	 		  	ZL 200780019497.X	 		  	6/20/2012
	 Denmark
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 Europe
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 Spain
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 France
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 Great Britain
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 India
	 	4187/KOLNP/2008	 		  	3/29/2007	 		  		 		  	
	 Italy
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 Japan
	 	2009-504212	 		  	3/29/2007	 		  	5245057	 		  	4/19/2013
	 Netherlands
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 Sweden
	 	07754382.5	 		  	3/29/2007	 		  	2007396	 		  	2/13/2013
	 United States
	 	11/727,927	 		  	3/29/2007	 		  	7,863,465	 		  	1/4/2011
	 WIPO
	 	PCT/US07/07856	 		  	3/29/2007	 		  		 		  	

  

  
 Page 3 of 4 

 PATENT SCHEDULE 

TITLE:        ANTIFUNGAL AGENTS 
  

															
	 Country
	 	 Application No.
	  	 	 	 Filing Date
	  	 	 	 Patent No.
	  	 	 	 Issue Date

	 Argentina
	 	P090103123	  		 	8/12/2009	  		 		  		 	
	 Australia
	 	2009 282 474	  		 	8/7/2009	  		 		  		 	
	 Brazil
	 	PI0912074-2	  		 	8/7/2009	  		 		  		 	
	 Belize
	 	658.11	  		 	8/7/2009	  		 		  		 	
	 Canada
	 	2,731,941	  		 	8/7/2009	  		 		  		 	
	 Chile
	 	00292-2011	  		 	8/7/2009	  		 		  		 	
	 China
	 	200980140485.1	  		 	8/7/2009	  		 		  		 	
	 Columbia
	 	11-016262	  		 	8/7/2009	  		 		  		 	
	 Costa Rica
	 	2011-0075	  		 	8/7/2009	  		 		  		 	
	 Dominican Republic
	 	P2011-0053	  		 	8/7/2009	  		 		  		 	
	 Algeria
	 	110102	  		 	8/7/2009	  		 		  		 	
	 Eurasia
	 	201100350	  		 	8/7/2009	  		 	018337	  		 	7/30/2013
	 Ecuador
	 	SP-11-10817	  		 	8/7/2009	  		 		  		 	
	 Egypt
	 	PCT250/2011	  		 	8/7/2009	  		 		  		 	
	 Europe
	 	09806944.6	  		 	8/7/2009	  		 		  		 	
	 Europe
	 	09806945.3	  		 	8/7/2009	  		 		  		 	
	 Gulf Coast
	 	14100	  		 	8/11/2009	  		 		  		 	
	 Guatemala
	 	A2011-0039	  		 	8/7/2009	  		 		  		 	
	 Hong Kong
	 	11112674.5	  		 	8/7/2009	  		 		  		 	
	 Honduras
	 	2011-000404	  		 	8/7/2009	  		 		  		 	
	 Indonesia
	 	W00201100885	  		 	8/7/2009	  		 		  		 	
	 Israel
	 	210975	  		 	8/7/2009	  		 		  		 	
	 India
	 	410/KOLNP/2011	  		 	8/7/2009	  		 		  		 	
	 Japan
	 	2011-522975	  		 	8/7/2009	  		 		  		 	
	 Korea
	 	10-2011-7005837	  		 	8/7/2009	  		 		  		 	
	 Lebanon
	 	5470	  		 	8/5/2009	  		 	8724	  		 	8/6/2009
	 Morocco
	 	33691	  		 	8/7/2009	  		 		  		 	
	 Mexico
	 	11/001656	  		 	8/7/2009	  		 	306141	  		 	12/14/2012
	 Mexico
	 	12/014669	  		 	12/13/2012	  		 		  		 	
	 Malaysia
	 	PI2011000483	  		 	8/7/2009	  		 		  		 	
	 Nicaragua
	 	2011-0035	  		 	8/7/2009	  		 		  		 	
	 New Zealand
	 	590,914	  		 	8/7/2009	  		 	590,914	  		 	3/5/2012
	 Peru
	 	000156-2011/DIN	  		 	8/7/2009	  		 		  		 	
	 Philippines
	 	1-2011-500251	  		 	8/7/2009	  		 		  		 	
	 Pakistan
	 	744/2009	  		 	8/6/2009	  		 		  		 	
	 Russia
	 	201100350	  		 	8/7/2009	  		 	018337	  		 	7/30/2013
	 Singapore
	 	201100626-9	  		 	8/7/2009	  		 	168675	  		 	5/15/2013
	 El Salvador
	 	E-3839-2011	  		 	8/7/2009	  		 		  		 	
	 Thai land
	 	0901003562	  		 	8/5/2009	  		 		  		 	
	 Tunisia
	 	TN2011/0050	  		 	8/7/2009	  		 		  		 	
	 Taiwan
	 	098126822	  		 	8/10/2009	  		 		  		 	
	 Ukraine
	 	a201102860	  		 	8/7/2009	  		 		  		 	
	 United States
	 	12/461,318	  		 	8/7/2009	  		 	8,188,085	  		 	5/29/2012
	 Venezuela
	 	2009-001516	  		 	8/12/2009	  		 		  		 	
	 Vietnam
	 	1-2011-00467	  		 	8/7/2009	  		 		  		 	
	 WIPO
	 	PCT/US09/004557	  		 	8/7/2009	  		 		  		 	
	 WIPO
	 	PCT/US09/004560	  		 	8/7/2009	  		 		  		 	
	 South Africa
	 	2011/00788	  		 	8/7/2009	  		 	2011/00788	  		 	5/30/2012

  

  
 Page 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]